What do medical sources say about Fluoxetine (Prozac, Prozac Weekly, Rapuflux, Selfemra, Sarafem) during pregnancy?

1st Trimester: MotherToBaby reports more than 10,000 first-trimester fluoxetine exposures with no pattern of birth defects, although some studies found heart-defect signals. A 2017 fluoxetine-specific meta-analysis found small increases in major and heart defects. A large 2014 US cohort found the adjusted SSRI heart-defect estimate fell and found no substantial increase attributable to antidepressant use. A 2026 US record study reported an adjusted hazard ratio of 1.63 for autism diagnoses with fluoxetine, but it lacked dose and duration data and independent confirmation of diagnoses, so it cannot show cause. Miscarriage findings differ: a 2014 Danish SSRI cohort found higher risk during use and after stopping before pregnancy, while a 2025 UK cohort found a small association overall and no increase among those treated before and during the first trimester. Ask your provider about your situation. 2nd Trimester: MotherToBaby reports that some studies link fluoxetine during pregnancy with early delivery or low birth weight, while untreated depression or anxiety can also affect pregnancy outcomes. A 2026 cohort across the UK, Norway, and Sweden found modest associations between antidepressant prescriptions and preterm birth and low Apgar scores at five minutes after birth; the stillbirth association weakened among mothers with depression or anxiety. The study abstract gives pooled estimates, while the full paper also assesses individual medicines. The Prozac label and MotherToBaby describe a possible association between later SSRI use and persistent pulmonary hypertension of the newborn. In a 2015 US cohort, late SSRI exposure had 31.5 cases per 10,000 births versus 20.8 without exposure; the adjusted odds ratio was 1.10 (95% CI 0.94-1.29). Ask your provider about your situation. 3rd Trimester: MotherToBaby reports temporary newborn symptoms after fluoxetine exposure near delivery, usually mild and resolving within weeks. In a 2024 cohort of term infants, delayed newborn adaptation occurred in 11.2% of those exposed to late-pregnancy SSRIs and 4.4% of unexposed infants; fluoxetine was among the medicines with the highest association. A 2015 cohort found persistent pulmonary hypertension of the newborn (PPHN) rates of 31.5 versus 20.8 per 10,000 births after late SSRI exposure; the adjusted overall odds ratio was 1.10 (95% CI 0.94-1.29) and the primary-PPHN-only odds ratio was 1.28. The Prozac label and UK MHRA say SSRI use, especially in the month before delivery, may increase postpartum bleeding risk based on observational data. These findings are SSRI-class results, not fluoxetine-specific PPHN or bleeding estimates. Ask your provider about your situation.

What do medical sources say about Fluoxetine (Prozac, Prozac Weekly, Rapuflux, Selfemra, Sarafem) while breastfeeding?

LactMed says fluoxetine and its active metabolite enter milk, and infant blood levels are found more often than with most SSRIs. Some infants have had colic, fussiness, or drowsiness, and studies differ on weight gain. In a 2025 cohort of 97 children, 81 mothers had used fluoxetine; additional SSRI exposure through milk was not linked to lower adjusted IQ scores, but the study measured IQ only. LactMed says fluoxetine needed by the mother is not by itself a reason to stop breastfeeding, while NHS SPS advises caution and monitoring for infant behavior, feeding, and weight. Ask your provider about your situation.

Where do sources disagree on Fluoxetine (Prozac, Prozac Weekly, Rapuflux, Selfemra, Sarafem) in pregnancy or breastfeeding?

First-trimester birth-defect findings MotherToBaby reports no pattern of birth defects among more than 10,000 first-trimester fluoxetine exposures. The Prozac label says evidence has not established an increased risk of major birth defects and that reported cardiovascular signals do not establish causation. A 2017 fluoxetine-specific meta-analysis found relative increases in major malformations and cardiovascular malformations. A large 2014 cohort found that associations for antidepressants weakened after adjustment for confounding. The meta-analysis pooled observational studies of fluoxetine, while the large US cohort assessed antidepressant and SSRI exposure and adjusted for depression and other factors. The designs and exposure estimates differ. The evidence does not establish a causal increase, but the fluoxetine-specific meta-analysis is a signal that should not be omitted. The corrected summary reports both the meta-analysis and the adjusted cohort result.

Back to search

Fluoxetine

Medication

Prozac, Prozac Weekly, Rapuflux, Selfemra, Sarafem

SSRI antidepressant

Pregnancy

Birth defects: MotherToBaby reports more than 10,000 first-trimester fluoxetine exposures and no pattern of defects. A 2017 meta-analysis of 16 cohort studies found relative increases in major malformations (RR 1.18, 95% CI 1.08-1.29) and cardiovascular malformations (RR 1.36, 95% CI 1.17-1.59). In a 2014 US cohort of 949,504 pregnancies, antidepressant associations with cardiac defects weakened after adjustment; the fully adjusted SSRI estimate was 1.06 (95% CI 0.93-1.22), and the authors found no substantial increase attributable to first-trimester antidepressant use. The meta-analysis was fluoxetine-specific, while the large cohort evaluated antidepressants and SSRI exposure with adjustment for confounding. Miscarriage: a 2014 Danish cohort found higher miscarriage hazard with early SSRI exposure (aHR 1.27) and a similar increase among women who stopped treatment 3-12 months before pregnancy (aHR 1.24). A 2025 UK cohort of 1,021,384 pregnancies found a small association for first-trimester antidepressant prescriptions overall (aHR 1.04; adjusted absolute risk 13.6% versus 13.1%), but no increase among those prescribed before pregnancy and during the first trimester (aHR 1.00). The miscarriage results cited here are antidepressant-class findings, not fluoxetine-specific estimates. Other outcomes: MotherToBaby describes possible preterm delivery and low birth weight, with untreated illness and other factors complicating interpretation. A 2026 UK, Norway, and Sweden cohort found antidepressant use associated with preterm delivery (aOR 1.26), low Apgar score (aOR 1.83), and stillbirth (aOR 1.16); among mothers with depression or anxiety, the stillbirth association attenuated (aOR 1.07, 95% CI 0.94-1.21). The paper includes individual-drug analyses, but the headline estimates cited here are pooled; exact fluoxetine-specific estimates from its supplementary figures were not extracted. PPHN: the Prozac label describes a possible SSRI risk later in pregnancy. Huybrechts et al. 2015 observed PPHN rates of 31.5 per 10,000 late-SSRI-exposed births and 20.8 per 10,000 unexposed births; the adjusted overall SSRI odds ratio was 1.10 (95% CI 0.94-1.29), while the primary-PPHN-only estimate was 1.28 (95% CI 1.01-1.64). Cornet et al. 2024 did not find a statistically significant association between SSRI exposure and pulmonary hypertension. Postpartum bleeding: the Prozac label reports an association with SSRI exposure, particularly in the month before delivery, of less than a 2-fold increase. The MHRA also notes a small increased risk based on observational studies. In a 2013 US Medicaid cohort of 106,000 women with mood or anxiety disorders, postpartum hemorrhage occurred in 4.0% of current serotonin reuptake inhibitor users and 2.8% of unexposed women with such disorders; the study did not estimate a fluoxetine-only effect. Neurodevelopment: a 2026 US electronic-record cohort studied 6,135,213 mother-child pairs and reported an adjusted ASD hazard ratio of 1.63 (95% CI 1.59-1.68) for fluoxetine, with 5,964 diagnoses among 108,268 exposed pairs. The authors lacked dose or duration data and had no independent confirmation of ASD diagnoses. A separate 2026 Wales cohort of 167,447 children found associations between maternal depression, antidepressant exposure, and special educational needs; the authors noted possible confounding by depression severity. Its fluoxetine-only subgroup assessed all-cause special educational needs, not fluoxetine-specific ASD. The 2026 results are observational and require replication.

Breastfeeding

LactMed reports more fluoxetine in milk than with most SSRIs and says norfluoxetine can be detected in many breastfed infants early postpartum. It reports colic, fussiness, and drowsiness, while studies differ on infant weight gain. LactMed found no adverse developmental effects in infants followed up to 5 years, but the older reports cannot determine whether breastfeeding caused the reported developmental findings. A 2025 prospective cohort tested 97 children at about age 5; 22 had postnatal SSRI exposure through breastfeeding, 37 were breastfed without postnatal SSRI exposure, and 38 were not breastfed. Eighty-one mothers (83.5%) had used fluoxetine. Adjusted IQ scores did not differ between breastfed children with and without postnatal SSRI exposure; other developmental outcomes were not evaluated. NHS SPS says fluoxetine can be used with caution, with sertraline or paroxetine preferred when clinically suitable, and advises monitoring for infant irritability, restlessness, drowsiness, feeding problems, and weight gain.

First-trimester birth-defect findings

Source A says: MotherToBaby reports no pattern of birth defects among more than 10,000 first-trimester fluoxetine exposures. The Prozac label says evidence has not established an increased risk of major birth defects and that reported cardiovascular signals do not establish causation. (MotherToBaby: Fluoxetine (Prozac), DailyMed: Prozac fluoxetine hydrochloride capsule label)
Source B says: A 2017 fluoxetine-specific meta-analysis found relative increases in major malformations and cardiovascular malformations. A large 2014 cohort found that associations for antidepressants weakened after adjustment for confounding. (Gao et al. 2017: Fluoxetine and congenital malformations, meta-analysis, Huybrechts et al. 2014: Antidepressant use in pregnancy and risk of cardiac defects)
Why they differ: The meta-analysis pooled observational studies of fluoxetine, while the large US cohort assessed antidepressant and SSRI exposure and adjusted for depression and other factors. The designs and exposure estimates differ.
What the evidence shows overall: The evidence does not establish a causal increase, but the fluoxetine-specific meta-analysis is a signal that should not be omitted. The corrected summary reports both the meta-analysis and the adjusted cohort result.

Miscarriage and antidepressant exposure

Source A says: MotherToBaby cites a small number of studies that did not find a greater chance of miscarriage with fluoxetine. The Prozac label says published data have not established an increased risk. (MotherToBaby: Fluoxetine (Prozac), DailyMed: Prozac fluoxetine hydrochloride capsule label)
Source B says: A Danish SSRI cohort found higher miscarriage hazard during early-pregnancy use and among people who stopped before pregnancy. A 2025 UK cohort found a small adjusted association for antidepressants overall, but no increase among those treated before and during the first trimester. (Andersen et al. 2014: SSRI exposure in early pregnancy and miscarriage, Martin et al. 2025: First-trimester antidepressant use and miscarriage, CPRD GOLD)
Why they differ: The studies are observational and use different comparators and adjustment methods. The Danish discontinuation comparison and the newer UK results show why illness and other factors may contribute. Neither study cited here supplies a fluoxetine-specific estimate.
What the evidence shows overall: Describe miscarriage evidence as mixed and class-level. Do not state that fluoxetine has no association or that it causes miscarriage.

Autism and other long-term developmental outcomes

Source A says: A 2026 US electronic-record cohort reported an adjusted ASD hazard ratio of 1.63 for fluoxetine compared with pregnancies not exposed to any study medication in the sterol-inhibiting medication group. It reported 5,964 diagnoses among 108,268 fluoxetine-exposed pairs. (Peeples et al. 2026: Sterol pathway disruption in pregnancy and autism)
Source B says: ACOG and SMFM statements from 2025 addressed the evidence available at that time. A 2026 Wales cohort found associations between special educational needs, maternal depression, and antidepressant exposure; the authors noted potential confounding by depression severity. The Wales paper included a fluoxetine-only analysis for all-cause special educational needs, not fluoxetine-specific ASD. (ACOG: Statement on the Benefit of Access to SSRIs During Pregnancy, SMFM Statement on SSRI Antidepressants for Treating Depression During Pregnancy, McIlvride et al. 2026: Prenatal depression, antidepressants, and child neurodevelopment)
Why they differ: The professional statements predate the 2026 cohorts. The US study reports a fluoxetine-specific association but lacks dose and duration data and independent confirmation of ASD diagnoses. The Wales cohort measured educational needs rather than a fluoxetine-specific ASD outcome and emphasizes possible confounding by illness severity.
What the evidence shows overall: The new fluoxetine-specific association is important and should be named, but it is observational and not yet independently replicated. It does not establish that fluoxetine caused ASD or identify a trimester-specific effect. Retain guidance and 4 stars while showing the uncertainty.

PPHN after late-pregnancy SSRI exposure

Source A says: The Prozac label and MotherToBaby describe a possible association between SSRI exposure later in pregnancy and PPHN. (DailyMed: Prozac fluoxetine hydrochloride capsule label, MotherToBaby: Fluoxetine (Prozac))
Source B says: In the 2015 cohort, the adjusted overall SSRI estimate was 1.10 (95% CI 0.94-1.29), while the primary-PPHN-only estimate was 1.28 (95% CI 1.01-1.64). A 2024 cohort did not find a statistically significant association with pulmonary hypertension. (Huybrechts et al. 2015: Antidepressant use late in pregnancy and PPHN, Cornet et al. 2024: SSRI treatment and delayed neonatal adaptation)
Why they differ: PPHN is rare, and studies use different case definitions and exposure windows. Adjustment changed the 2015 overall estimate, while its primary-PPHN subset remained just above the null. The 2024 cohort assessed late-pregnancy SSRI exposure and did not find a statistically significant association with pulmonary hypertension.
Other sources: EMA PRAC reviewed a 2022 signal about pulmonary hypertension in patients and found insufficient evidence for a causal association. That review concerns pulmonary hypertension in patients, not neonatal PPHN, so it does not directly resolve the newborn evidence. (EMA PRAC: Minutes on pulmonary hypertension signal, September 2022)
What the evidence shows overall: Keep the label wording visible, but replace the unsourced broad less-than-one-percent wording with named cohort rates and estimates. These are SSRI-class findings, not fluoxetine-specific estimates.

2025 FDA expert panel and professional society statements

Source A says: The FDA page documents an expert panel meeting on July 21, 2025, but it is a meeting notice and does not state an FDA safety conclusion. (FDA Expert Panel on SSRIs and Pregnancy, meeting notice)
Source B says: ACOG and SMFM publicly challenged claims made by panelists and supported access to SSRI treatment during pregnancy, while emphasizing risks of untreated or undertreated depression. (ACOG: Statement on the Benefit of Access to SSRIs During Pregnancy, SMFM Statement on SSRI Antidepressants for Treating Depression During Pregnancy)
Why they differ: The FDA page is an event notice, not a regulatory safety action or a published agency finding. ACOG and SMFM issued professional society responses to the panelists’ claims.
What the evidence shows overall: Show the public disagreement, but do not attribute panelists’ claims to FDA as an agency position. No pregnancy-specific FDA label change or HHS statement was identified by the audit cutoff.

Last reviewed 2026-10-14

Independent check 2026-10-14

Not yet clinician-reviewed

Ask your provider about your situation.

Fluoxetine

Fluoxetine — Breastfeeding

What the research shows

What's in it / what was tested

Sources disagree

Options sources describe

Beyond pregnancy

All sources

Similar medications